View Post

Mayo Breast Cancer Vaccine Could Be Available In Less Than A Decade

In Clinical Trials by Barbara Jacoby

By: Robin Seaton Jefferson From: forbes.com Researchers at Mayo Clinic in Jacksonville, Florida say a vaccine they have developed could be available within eight years that may not only stop the recurrence of breast and ovarian cancers, but prevent them from developing in the first place. “It is reasonable to say that we could have a vaccine within eight years …

View Post

Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in HER2CLIMB-02, a randomized phase 3 clinical trial evaluating investigational agent tucatinib versus placebo, in combination with standard-of-care ado-trastuzumab emtansine (T-DM1, Kadcyla®), for patients with locally advanced or metastatic HER2-positive (HER2+) breast cancer. This trial is intended to support registration in the U.S. Tucatinib is an oral, …

View Post

Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol

In Clinical Trials by Barbara Jacoby

Source: Datar Cancer Genetics From: PR Newswire – RESILIENT Protocol captures Encyclopedic information from tumors and uses Artificial Intelligence (AI) to optimize treatments; – Objective Response and Disease Control Comparable to or better than most Immunotherapy options; – Unique Ultra-personalised combination of drugs already approved for cancer; – RESILIENT Protocol commercially launched Datar Cancer Genetics, a cancer research company, today …

View Post

Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer

In Clinical Trials by Barbara Jacoby

From: PR Newswire – The initiated study will further evaluate the antitumor activity, safety and tolerability of bavituximab plus KEYTRUDA® in a gastric cancer population – Oncologie’s first global study for bavituximab plans enrollment in the US, UK, Taiwan and South Korea Oncologie, a biopharmaceutical company using an innovative precision medicine platform to develop next-generation oncology therapeutics, announced today the …

View Post

New Colorectal Cancer Vaccine May Help Pancreatic Patients Too

In Clinical Trials by Barbara Jacoby

By: Ivanhoe Newswire From: nbcdfw.com Surgery and chemotherapy have long been the primary treatment options for colorectal cancer. Even then, survival rates can be low, if the cancer is not detected early. Now, researchers are fighting back with a simple vaccine meant to activate the body’s immune cells and destroy cancer cells. There is hope it might also target other …

View Post

Promising Combinations Surpass Standard of Care in Advanced Renal Cell Carcinoma

In Clinical Trials by Barbara Jacoby

By: Nichole Tucker From: targetedonc.com Multiple studies have shown combinations of checkpoint inhibitors and chemotherapy prolong progression-free survival (PFS) and improve overall survival (OS) in patients with RCC. In the CheckMate 214 study of nivolumab (Opdivo) plus ipilimumab (Yervoy) versus sunitinib (NCT02231749) in advanced disease patients, those who received the combination achieved higher OS rates at 18 months(75% vs 60%) …

View Post

Breast Cancer Drugs More Effective Than Hormone Therapy For Some Prostate Cancers

In Clinical Trials by Barbara Jacoby

Source: The Institute of Cancer Research From: technologynetworks.com A drug used for breast and ovarian cancer is more effective than modern targeted hormone treatments at slowing progression and improving survival in some men with advanced prostate cancer, Phase III clinical trial findings reveal. The PROfound trial compared the genetically targeted cancer drug olaparib – already licensed for women with breast …

View Post

New Evolution-Busting Drug Overcomes Resistance in Aggressive Breast Cancers

In Clinical Trials by Barbara Jacoby

By: Institute of Cancer Research From: scitechdaily.com A new type of drug that blocks one of cancer’s key evolutionary escape routes from chemotherapy could be used to treat aggressive breast cancers, a new study has shown. Scientists at The Institute of Cancer Research, London, found that the drug could reinvigorate the response to chemotherapy in cancers that had become resistant, …

View Post

Poziotinib Shows Promise in Hard-to-Treat NSCLC Exon 20 Mutations

In Clinical Trials by Barbara Jacoby

By: Rachel Narozniak From: onclive.com Poziotinib, a novel drug that targets relatively uncommon EGFR and HER2 exon 20 insertion mutations, is being tested in a biomarker-driven trial of patients with non–small cell lung cancer (NSCLC) in both second-line and treatment-naïve settings. The phase II ZENITH20 trial (NCT03318939) is evaluating poziotinib monotherapy, an orally available agent, across 7 cohorts based on …

View Post

TAILORx High-Risk Group Analysis Adds to Oncotype DX Chemo-Prediction Data

In Clinical Trials by Barbara Jacoby

By: Staff Reporter From: genomeweb.com In secondary analysis of data from the TAILORx trial, researchers have added new confirming evidence that patients with high risk scores from Genomic Health’s Oncotype DX appear to benefit significantly from added chemotherapy. Investigators led by the trial’s PI Joseph Sparano shared their findings in JAMA Oncology today and also presented the analysis at the …